DEXCOM INC (DC4.DE) Stock Fundamental Analysis
FRA:DC4 - US2521311074 - Common Stock
65.16 EUR
-0.03 (-0.05%)
We assign a fundamental rating of 6 out of 10 to DC4. DC4 was compared to 57 industry peers in the Health Care Equipment & Supplies industry. DC4 has an excellent profitability rating, but there are some minor concerns on its financial health. DC4 is valued quite expensive, but it does show an excellent growth. With these ratings, DC4 could be worth investigating further for growth investing!.
1. Profitability
1.1 Basic Checks
In the past year DC4 was profitable.
In the past year DC4 had a positive cash flow from operations.
In the past 5 years DC4 has always been profitable.
DC4 had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 7.80%, DC4 belongs to the top of the industry, outperforming 80.70% of the companies in the same industry.
The Return On Equity of DC4 (22.21%) is better than 91.23% of its industry peers.
DC4's Return On Invested Capital of 14.52% is amongst the best of the industry. DC4 outperforms 94.74% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for DC4 is above the industry average of 8.81%.
The 3 year average ROIC (11.25%) for DC4 is below the current ROIC(14.52%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.8% | ||
| ROE | 22.21% | ||
| ROIC | 14.52% |
ROA(3y)7.95%
ROA(5y)8.21%
ROE(3y)23.2%
ROE(5y)22.06%
ROIC(3y)11.25%
ROIC(5y)9.23%
1.3 Margins
DC4 has a better Profit Margin (13.29%) than 78.95% of its industry peers.
DC4's Profit Margin has improved in the last couple of years.
DC4 has a Operating Margin of 17.22%. This is in the better half of the industry: DC4 outperforms 77.19% of its industry peers.
In the last couple of years the Operating Margin of DC4 has grown nicely.
Looking at the Gross Margin, with a value of 60.01%, DC4 is in line with its industry, outperforming 59.65% of the companies in the same industry.
DC4's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 17.22% | ||
| PM (TTM) | 13.29% | ||
| GM | 60.01% |
OM growth 3Y10.52%
OM growth 5Y8.87%
PM growth 3Y17.27%
PM growth 5Y15.84%
GM growth 3Y-3.98%
GM growth 5Y-0.72%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so DC4 is still creating some value.
The number of shares outstanding for DC4 has been increased compared to 1 year ago.
DC4 has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, DC4 has an improved debt to assets ratio.
2.2 Solvency
DC4 has an Altman-Z score of 5.32. This indicates that DC4 is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.32, DC4 belongs to the top of the industry, outperforming 87.72% of the companies in the same industry.
DC4 has a debt to FCF ratio of 4.38. This is a neutral value as DC4 would need 4.38 years to pay back of all of its debts.
The Debt to FCF ratio of DC4 (4.38) is better than 63.16% of its industry peers.
DC4 has a Debt/Equity ratio of 0.50. This is a neutral value indicating DC4 is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.50, DC4 is in line with its industry, outperforming 40.35% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 4.38 | ||
| Altman-Z | 5.32 |
ROIC/WACC1.79
WACC8.11%
2.3 Liquidity
A Current Ratio of 1.52 indicates that DC4 should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.52, DC4 is in line with its industry, outperforming 45.61% of the companies in the same industry.
DC4 has a Quick Ratio of 1.35. This is a normal value and indicates that DC4 is financially healthy and should not expect problems in meeting its short term obligations.
DC4 has a Quick ratio of 1.35. This is in the better half of the industry: DC4 outperforms 66.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.52 | ||
| Quick Ratio | 1.35 |
3. Growth
3.1 Past
DC4 shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.86%.
Measured over the past years, DC4 shows a very strong growth in Earnings Per Share. The EPS has been growing by 29.25% on average per year.
Looking at the last year, DC4 shows a quite strong growth in Revenue. The Revenue has grown by 9.30% in the last year.
DC4 shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 22.27% yearly.
EPS 1Y (TTM)-2.86%
EPS 3Y35.38%
EPS 5Y29.25%
EPS Q2Q%11.63%
Revenue 1Y (TTM)9.3%
Revenue growth 3Y18.1%
Revenue growth 5Y22.27%
Sales Q2Q%15.21%
3.2 Future
DC4 is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.00% yearly.
DC4 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.08% yearly.
EPS Next Y26.67%
EPS Next 2Y25.95%
EPS Next 3Y24.52%
EPS Next 5Y23%
Revenue Next Year15.01%
Revenue Next 2Y15.3%
Revenue Next 3Y14.94%
Revenue Next 5Y14.08%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 44.63 indicates a quite expensive valuation of DC4.
Compared to the rest of the industry, the Price/Earnings ratio of DC4 is on the same level as its industry peers.
When comparing the Price/Earnings ratio of DC4 to the average of the S&P500 Index (27.13), we can say DC4 is valued expensively.
A Price/Forward Earnings ratio of 29.02 indicates a quite expensive valuation of DC4.
DC4's Price/Forward Earnings is on the same level as the industry average.
When comparing the Price/Forward Earnings ratio of DC4 to the average of the S&P500 Index (22.76), we can say DC4 is valued slightly more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 44.63 | ||
| Fwd PE | 29.02 |
4.2 Price Multiples
The rest of the industry has a similar Enterprise Value to EBITDA ratio as DC4.
DC4's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 52.19 | ||
| EV/EBITDA | 28.25 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
DC4 has an outstanding profitability rating, which may justify a higher PE ratio.
DC4's earnings are expected to grow with 24.52% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.67
PEG (5Y)1.53
EPS Next 2Y25.95%
EPS Next 3Y24.52%
5. Dividend
5.1 Amount
DC4 does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:DC4 (8/27/2025, 7:00:00 PM)
65.16
-0.03 (-0.05%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners97.5%
Inst Owner ChangeN/A
Ins Owners0.26%
Ins Owner ChangeN/A
Market Cap25.55B
Analysts85.29
Price Target89.58 (37.48%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.34%
Min EPS beat(2)-4.09%
Max EPS beat(2)6.77%
EPS beat(4)2
Avg EPS beat(4)-1.87%
Min EPS beat(4)-11.66%
Max EPS beat(4)6.77%
EPS beat(8)6
Avg EPS beat(8)9.43%
EPS beat(12)10
Avg EPS beat(12)14.38%
EPS beat(16)11
Avg EPS beat(16)8.49%
Revenue beat(2)1
Avg Revenue beat(2)0.34%
Min Revenue beat(2)-0.19%
Max Revenue beat(2)0.88%
Revenue beat(4)1
Avg Revenue beat(4)-0.54%
Min Revenue beat(4)-1.66%
Max Revenue beat(4)0.88%
Revenue beat(8)2
Avg Revenue beat(8)-0.78%
Revenue beat(12)5
Avg Revenue beat(12)-0.39%
Revenue beat(16)6
Avg Revenue beat(16)-0.42%
PT rev (1m)1.41%
PT rev (3m)-0.53%
EPS NQ rev (1m)-0.44%
EPS NQ rev (3m)2.46%
EPS NY rev (1m)0.93%
EPS NY rev (3m)1.11%
Revenue NQ rev (1m)-0.08%
Revenue NQ rev (3m)0.25%
Revenue NY rev (1m)0.25%
Revenue NY rev (3m)0.32%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 44.63 | ||
| Fwd PE | 29.02 | ||
| P/S | 6.93 | ||
| P/FCF | 52.19 | ||
| P/OCF | 30.16 | ||
| P/B | 11.58 | ||
| P/tB | 12.1 | ||
| EV/EBITDA | 28.25 |
EPS(TTM)1.46
EY2.24%
EPS(NY)2.25
Fwd EY3.45%
FCF(TTM)1.25
FCFY1.92%
OCF(TTM)2.16
OCFY3.32%
SpS9.41
BVpS5.63
TBVpS5.38
PEG (NY)1.67
PEG (5Y)1.53
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.8% | ||
| ROE | 22.21% | ||
| ROCE | 18.43% | ||
| ROIC | 14.52% | ||
| ROICexc | 53.56% | ||
| ROICexgc | 59.66% | ||
| OM | 17.22% | ||
| PM (TTM) | 13.29% | ||
| GM | 60.01% | ||
| FCFM | 13.27% |
ROA(3y)7.95%
ROA(5y)8.21%
ROE(3y)23.2%
ROE(5y)22.06%
ROIC(3y)11.25%
ROIC(5y)9.23%
ROICexc(3y)35.45%
ROICexc(5y)29.66%
ROICexgc(3y)40.94%
ROICexgc(5y)33.19%
ROCE(3y)14.28%
ROCE(5y)11.73%
ROICexcg growth 3Y55.18%
ROICexcg growth 5Y18.96%
ROICexc growth 3Y50.14%
ROICexc growth 5Y16.58%
OM growth 3Y10.52%
OM growth 5Y8.87%
PM growth 3Y17.27%
PM growth 5Y15.84%
GM growth 3Y-3.98%
GM growth 5Y-0.72%
F-Score6
Asset Turnover0.59
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 4.38 | ||
| Debt/EBITDA | 1.33 | ||
| Cap/Depr | 176.58% | ||
| Cap/Sales | 9.69% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 101.12% | ||
| Profit Quality | 99.88% | ||
| Current Ratio | 1.52 | ||
| Quick Ratio | 1.35 | ||
| Altman-Z | 5.32 |
F-Score6
WACC8.11%
ROIC/WACC1.79
Cap/Depr(3y)175.34%
Cap/Depr(5y)240.83%
Cap/Sales(3y)9.32%
Cap/Sales(5y)10.84%
Profit Quality(3y)97.76%
Profit Quality(5y)73.64%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.86%
EPS 3Y35.38%
EPS 5Y29.25%
EPS Q2Q%11.63%
EPS Next Y26.67%
EPS Next 2Y25.95%
EPS Next 3Y24.52%
EPS Next 5Y23%
Revenue 1Y (TTM)9.3%
Revenue growth 3Y18.1%
Revenue growth 5Y22.27%
Sales Q2Q%15.21%
Revenue Next Year15.01%
Revenue Next 2Y15.3%
Revenue Next 3Y14.94%
Revenue Next 5Y14.08%
EBIT growth 1Y6.1%
EBIT growth 3Y30.52%
EBIT growth 5Y33.11%
EBIT Next Year76.6%
EBIT Next 3Y38.89%
EBIT Next 5Y31.85%
FCF growth 1Y22.49%
FCF growth 3Y127.88%
FCF growth 5Y36.21%
OCF growth 1Y28.04%
OCF growth 3Y30.77%
OCF growth 5Y25.76%